| Literature DB >> 31757101 |
Li-Ru Chen1,2, Peng-Hsuan Hou1, Kuo-Hu Chen3,4.
Abstract
Osteoporosis is a vital healthcare issue among elderly people. During the aging process, a gradual loss of bone mass results in osteopenia and osteoporosis. Heritable factors account for 60%-80% of optimal bone mineralization, whereas modifiable factors such as nutrition, weight-bearing exercise, body mass, and hormonal milieu affect the development of osteopenia and osteoporosis in adulthood. Osteoporosis substantially increases the risk of skeletal fractures and further morbidity and mortality. The effective prevention of fractures by reducing the loss of bone mass is the primary goal for physicians treating people with osteoporosis. Other than pharmacologic agents, lifestyle adjustment, nutritional support, fall prevention strategies, exercise, and physical modalities can be used to treat osteoporosis or prevent further osteoporotic fracture. Each of these factors, alone or in combination, can be of benefit to people with osteoporosis and should be implemented following a detailed discussion with patients. This review comprises a systematic survey of the current literature on osteoporosis and its nonpharmacologic and nonsurgical treatment. It provides clinicians and healthcare workers with evidence-based information on the assessment and management of osteoporosis. However, numerous issues regarding osteoporosis and its treatment remain unexplored and warrant future investigation.Entities:
Keywords: calcium; exercise; osteoporosis; physical modality; vitamin D
Mesh:
Year: 2019 PMID: 31757101 PMCID: PMC6950804 DOI: 10.3390/nu11122848
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Figure 1The pathways underlying the formation and action of osteoblasts, osteoclasts, and subsequent osteoporosis. M-CSF can promote the proliferation of osteoclasts; Wnt signaling can stimulate the differentiation of BMSCs into osteoblasts. Estrogen can both increase the secretion of OPG and decrease secretion of RANKL, thus preventing the combination of RANKL-RANK to activate osteoclastogenesis. BMSCs, bone marrow stromal cells; OPG, osteoprotegerin; RANKL, receptor activator of nuclear factor-κB (NF-κB) ligand).